Melior Discovery
 | |
| Company type | Private company |
|---|---|
| Industry | Biotechnology |
| Founded | 2005 |
| Founder | Andrew Reaume Michael Saporito |
| Headquarters | Exton, Pennsylvania |
| Products | Pharmaceuticals, contract research |
| Website | www |
Melior Discovery, Inc. is a private biopharmaceutical company based in Exton, Pennsylvania, USA.
Products and services
[edit]The company specializes in drug repositioning and has established a proprietary phenotypic screening platform that it uses for this purpose. Melior also offers certain contract research organization (CRO) services comprising animal models representing different disease conditions.[citation needed]
The Company has issued press releases disclosing partnerships with Pfizer, Merck & Co., Johnson & Johnson, and AstraZeneca, all citing the use of the company's drug repositioning technology. Melior Discovery has also used its technology to discover its own drug candidates.[citation needed]
History
[edit]Melior Discovery was co-founded in 2005 by Dr. Andrew Reaume (President and CEO) and Dr. Michael Saporito (Vice President of Research).[1] Its investors include Cammeby's Capital Group, VenturEast, Osage Ventures, Mid-Atlantic Angel Group, and BioAdvance.[2]
In March 2009, the Food and Drug Administration (FDA) approved the company's Investigational New Drug (IND) application for a type 2 diabetes therapeutic candidate, MLR-1023.[3] In 2013, the company reported a licensing partnership with Bukwang Pharmaceutical Company LTD[4] and the initiation of clinical trials in March 2015.[5] In June 2016, the company reported positive results from their Phase 2a clinical study in diabetic subjects.[6]
References
[edit]- ^ "NGP Europe - Drug Discovery - Productivity Crisis - Innovation Gap | GDS Publishing". Ngpharma.eu.com. 2011-05-26. Archived from the original on 2012-03-03. Retrieved 2012-08-09.
- ^ EDGAR Search
- ^ "The FDA also approved Melior discovery's IND application for the clinical development of its novel first-in-class kinase activator, MLR-1023, for the treatment of Type 2 diabetes. (New Drug Applications)". 2009-04-01.
{{cite web}}: Missing or empty|url=(help) - ^ "Melior Licenses Novel Diabetes Drug to Bukwang Pharmaceutical Co" (Press release). Business Wire. 4 December 2013. Retrieved December 4, 2013.
- ^ "Melior Pharmaceuticals Initiates Phase 2 Study with MLR-1023 for Type 2 Diabetes" (Press release). Business Wire. 3 March 2015. Retrieved March 3, 2015.
- ^ "Melior Pharmaceuticals Announces Positive Phase 2A Results in Type 2 Diabetes Study". www.businesswire.com. 2016-06-13. Retrieved 2019-12-11.
